How cells control nuclear size becomes clearer

July 11, 2017

Over a century since scientists first observed that cells and their nucleus grow at a constant ratio to each other, we are now closer to finding out how.

The cell cycle, the process of cell growth and division that sees "daughter" cells enlarge before dividing again, includes the nucleus - the cell's condensed genetic control center - simultaneously dividing and enlarging hand-in-hand with their cell.

The mechanism involved in this in-tandem augmentation has proven one of the great-unanswered questions of cell biology; the bigger the cell the bigger the nucleus, but what controls this proportional enlargement?

Assistant Professor Kazunori Kume of Hiroshima University, through his latest research into yeast cells, has discovered that the hoarding of genetic materials (mRNA) and proteins by the nucleus causes it to bulk up. He further proposes that this swelling is enabled by controlling the transport of mRNA and proteins from the nucleus into the encompassing liquid cytoplasm, and the amount of nuclear membrane supplied via lipid synthesis.

As it is already known that the consistent size ratio between cells and nuclei deviates with age, and also due to cancer, it is hoped these new findings could assist our understanding of body degeneration and its prevention.

Yeast, a single celled organism, shares many characteristics and a size similar to cells found in humans and other eukaryotes.

This latest discovery saw Assistant Professor Kume, from HU's Research Center for Healthy Aging, carry out a comprehensive search of the fission yeast genome in the hope of finding illusive genes that determine nucleus size.

Knowing that of the 5000 genes found in fission yeast, 2000 are essential for cell growth, he looked at the other 3000 in the hope that some might be involved in controlling the size of the nucleus instead.

One-by-one each of these 3000 genes was removed in isolation and the resultant mutated yeast cell was observed under the microscope.

By recording the dimensions of each of the resultant cells and their nucleus, he was able to calculate a cell-to-nucleus ratio - a painstaking process that paid off. He found 14 genes whose deletion lead to a greater cell-to-nucleus ratio than the usual 0.08, suggesting they were responsible for this ratio's maintenance.

Further investigation into these nuclei showed that the usual mechanisms required for transporting mRNA from inside the nucleus, where it is produced, to outside into the cell's cytoplasm, where it is required for protein production, was defective - meaning the mRNA couldn't get out!

mRNA molecules contain genetic information for producing proteins and true to form, analysis of the larger mutated nuclei showed that they contained, not only a higher concentration of mRNA but also mRNA derived proteins, causing them to swell.

This nuclear swelling was also seen to be dependent on lipid production, which is required for nuclear membrane expansion. Interestingly the researchers found that even disruption of lipid production alone deregulated nuclear membrane growth, resulting in an increased nuclear size.

While this research finally shines a light on cell-to-nucleus ratio maintenance, Assistant Professor Kume admits there is still a long way to go before they can fully understand what is occurring:

"There are so many questions that now need answering, what triggers these membrane changes? Does nuclear expansion cause cancer or result from it? What causes these specific genes to mutate? This research is just the first step into the unknown, It means I now have leads to follow and more mysteries to solve!"

Hiroshima University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to